ArsenalBio
ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot
ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership
ArsenalBio Secures $325M Funding to Advance Programmable CAR-T Therapies
ArsenalBio, CAR-T therapies, biotech funding, programmable cell therapies, solid tumors, Regeneron, BMS
ArsenalBio Secures $325M in Series C Funding for Solid Tumor Cell Therapy Trials
ArsenalBio, cell therapy, solid tumor trials, Series C funding, biotech investment